Healthcare / Health Information ServicesNasdaqGM
$4.63
+0.35 (+8.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $86948.00 · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$224M
P/E
18.5x
↓EV/EBITDA
N/A
•ROE
62.0%
↑Gross Margin
85.7%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+54.6%
FCF CAGR
—
FCF margin
-0.6%
FCF / Net income
-0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $194.1M · net income $14.4M · FCF $-1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $194.1M | $194.1M | $154.8M | $152.5M | $119.0M | $92.9M | $37.3M | $12.5M | $42515.00 | $5.0M | $5.0M | $1.2M | $714158.00 | $808363.00 | $673778.00 |
| Net Income | $14.4M | $14.4M | $-21.4M | $-20.6M | $-45.5M | $-60.9M | $-58.6M | $-3.1M | $-1.2M | $-1.2M | $-1.1M | $-61992.00 | $-460485.00 | $-268262.00 | $-445649.00 |
| EBITDA | $-1.5M | $-1.5M | $-14.2M | $-7.9M | $-35.9M | — | — | — | — | — | — | — | — | — | — |
| EPS | 0.25 | 0.25 | -0.53 | -0.70 | -1.57 | — | — | — | — | -0.15 | -0.15 | — | — | — | — |
| Gross Margin | 85.7% | 85.7% | 86.2% | 87.6% | 84.3% | 80.6% | 76.2% | 79.7% | 14883.9% | 53.3% | 65.9% | 79.7% | 75.8% | 77.6% | 70.3% |
| Operating Margin | -4.0% | -4.0% | -13.2% | -9.5% | -33.3% | -58.5% | -155.0% | -23.2% | -4836.3% | -24.6% | -23.5% | -21.5% | -74.3% | -67.6% | -80.1% |
| Net Margin | 7.4% | 7.4% | -13.8% | -13.5% | -38.3% | -65.6% | -157.3% | -25.2% | -2918.6% | -24.1% | -22.2% | -5.1% | -64.5% | -33.2% | -66.1% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.27 | 0.27 | -2.74 | 5.40 | -0.60 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.04 | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-1.2M | $-1.2M | $9.3M | $86948.00 | $-35.8M | $-33.3M | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||
| ROE | 62.0% | 62.0% | 235.7% | -587.6% | 666.7% | -267.8% | 2547.8% | 317.5% | -138.2% | -136.7% | 311.8% | -61.9% | 330.1% | -137.2% | -330.1% |
| Valuation | |||||||||||||||
| P/E | 18.52 | 18.52 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 9.02 | 9.02 | — | 52.71 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 25.3% | 25.3% | 1.5% | 28.2% | — | 149.0% | 199.1% | 29227.5% | -99.1% | 0.0% | 310.2% | 70.7% | -11.7% | 20.0% | — |
| EPS Growth | 147.2% | 147.2% | 24.3% | 55.4% | — | — | — | — | — | 0.0% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.0%
EPS terminal req.
$0.41
Spread vs growth
129.2%
5Y implied EPS CAGR
14.7%
EPS terminal req.
$0.50
Spread vs growth
132.4%
10Y implied EPS CAGR
12.3%
EPS terminal req.
$0.80
Spread vs growth
134.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-62.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.53 → 0.25
Residual
-62.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.